Selinexor

Brand names: Xpovio · Active ingredient: Selinexor

In short: XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple

Forms & strengthsTablets: 10 mg, blue, round, bi-convex, film-coated tablets with “X10” debossed on one side and nothing on the other side. 20 mg, blue, round, bi-convex, film-coated tablets with “K20” debossed on one side and nothing on the other side. …
LabelKaryopharm Therapeutics Inc.
Label updatedMay 13, 2026

What is Selinexor used for?

XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Selinexor dosage

In Combination with Bortezomib and Dexamethasone (XVd)

The recommended dosage of XPOVIO is 100 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with:

Bortezomib 1.3 mg/m2 administered subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off.

Dexamethasone 20 mg taken orally twice weekly on Days 1 and 2 of each week.

Refer to Clinical Studies (14.1) and the prescribing information of bortezomib and dexamethasone for additional dosing information.

In Combination with Dexamethasone (Xd)

The recommended dosage of XPOVIO is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20 mg taken orally with each dose of XPOVIO on Days 1 and 3 of each week.

For additional information regarding the administration of dexamethasone, refer to its prescribing information.

Monitor complete blood count (CBC) with differential, standard blood chemistries, body weight, nutritional status, and volume status at baseline and during treatment as clinically indicated. Monitor more frequently during the first three months of treatment . Assess the need for dosage modifications of XPOVIO for adverse reactions .

Advise patients to maintain adequate fluid and caloric intake throughout treatment. Consider intravenous hydration for patients at risk of dehydration .

Provide prophylactic antiemetics. Administer a 5-HT3 receptor antagonist and other anti-nausea agents prior to and during treatment with XPOVIO .

Recommended XPOVIO dosage reduction steps are presented in Table 1.

Recommended Starting Dosage | Multiple Myeloma

In Combination with Bortezomib and Dexamethasone (XVd) | Multiple Myeloma

In Combination with Dexamethasone (Xd)

100 mg once weekly | 80 mg Days 1 and 3 of each week(160 mg total per week)

First Reduction | 80 mg once weekly | 100 mg once weekly

Second Reduction | 60 mg once weekly | 80 mg once weekly

Third Reduction | 40 mg once weekly | 60 mg once weekly

Fourth Reduction | Permanently discontinue | Permanently discontinue

Recommended dosage modifications for hematologic adverse reactions in patients with multiple myeloma are presented in Table 2. Recommended dosage modifications for non-hematologic adverse reactions are presented in Table 3.

Adverse Reaction | Occurrence | Action

Thrombocytopenia

Platelet count 25,000 to less than 75,000/mcL | Any | Reduce XPOVIO by 1 dose level .

Platelet count 25,000 to less than 75,000/mcL with concurrent bleeding | Any | Interrupt XPOVIO.

Restart XPOVIO at 1 dose level lower after bleeding has resolved.

Administer platelet transfusions per clinical guidelines.

Platelet count less than 25,000/mcL | Any | Interrupt XPOVIO. …

How to take Selinexor — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Dosing Instructions

:

Instruct patients to take XPOVIO exactly as prescribed.

Advise patients to swallow the tablet whole with water. The tablet should not be broken, chewed, crushed, or divided.

If a patient misses a dose, advise them to take their next dose at its regularly scheduled time. If a patient vomits or misses a dose of XPOVIO, advise them to take the next dose on the next regularly scheduled day.

Advise patients that XPOVIO comes in a child-resistant blister pack.

Advise patients to take their prescribed dexamethasone (if applicable) and prophylactic anti-nausea medications as directed .

Advise patients that blood tests and body weight will be monitored at baseline and during treatment as clinically indicated, with more frequent monitoring during the first three months of treatment .

Advise patients to maintain appropriate fluid and caloric intake throughout their treatment .

Hematologic Adverse Reactions

Thrombocytopenia

Advise patients that they may develop low platelet counts (thrombocytopenia). Symptoms of thrombocytopenia may include bleeding and easy bruising. …

Warnings & precautions

Do not take this medicine if: None.

XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia is the leading cause of dosage modifications .

In patients with multiple myeloma who received XPOVIO 100 mg once weekly (BOSTON, n=195), thrombocytopenia was reported in 92% of patients and severe (Grade 3-4) thrombocytopenia was reported in 43% of patients. The median time to first onset was 22 days for any grade thrombocytopenia and 43 days for Grade 3 or 4 thrombocytopenia. Bleeding occurred in 16% of patients with thrombocytopenia, clinically significant bleeding (Grade ≥3 bleeding) occurred in 4% of patients with thrombocytopenia, and fatal hemorrhage occurred in 2% of patients with thrombocytopenia. Permanent discontinuations of XPOVIO due to thrombocytopenia occurred in 2% of patients.

In patients with multiple myeloma who received XPOVIO 80 mg twice weekly (STORM, n=202), thrombocytopenia was reported as an adverse reaction in 74% of patients and severe (Grade 3-4) thrombocytopenia was reported in 61% of patients. The median time to onset of the first event was 22 days. Bleeding occurred in 23% of patients with thrombocytopenia, clinically significant bleeding occurred in 5% of patients with thrombocytopenia, and fatal hemorrhage occurred in <1% of patients.

Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first three months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction .

XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection . …

Selinexor side effects

The following clinically significant adverse reactions are described in detail in other labeling sections:

Thrombocytopenia .

Neutropenia .

Gastrointestinal Toxicity .

Hyponatremia .

Serious Infection .

Neurological Toxicity .

Cataract .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Multiple Myeloma

XPOVIO in Combination with Bortezomib and Dexamethasone (XVd)

The safety of XPOVIO in combination with bortezomib and dexamethasone was evaluated in BOSTON . Patients were randomized to receive XPOVIO 100 mg orally once weekly in combination with bortezomib and dexamethasone (XVd) (n=195) or bortezomib and dexamethasone (Vd) (n=204). Among patients who received XPOVIO, the median duration of XPOVIO treatment was 29 weeks (range: 1 to 120 weeks) and the median dose was 80 mg (range: 30 to 137 mg) per week.

Serious adverse reactions occurred in 52% of patients who received XPOVIO in combination with bortezomib and dexamethasone. Serious adverse reactions in >3% of patients included pneumonia (14%), sepsis, diarrhea and vomiting (4% each). Fatal adverse reactions occurred in 6% of patients within 30 days of last treatment, including pneumonia (n=3) and sepsis (n=3). …

About this medicine

Selinexor is a nuclear export inhibitor. Selinexor is (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N'-(pyrazin-2-yl)prop-2-enehydrazide. It is a white to off-white powder and has the molecular formula C17H11F6N7O and a molecular mass of 443.31 g/mol. The molecular structure is shown below:

XPOVIO tablets for oral dosing are supplied in six strengths, with each tablet containing 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, or 80 mg of selinexor as the active ingredient. The inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, Opadry 200 clear, Opadry II blue, povidone K30, and sodium lauryl sulfate.

How it works: In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus and reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f6dd2682-75a6-4863-90a8-a3197f6f78a8. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate